Activator of blood clotting for the efficient termination of bleedings

City: Kyiv

Project manager: Nataliia Lugovska

Degree of project readiness: MVP  

One of the serious consequences of disasters or military conflicts is injuries, accompanied by massive bleeding. 

To reliably stop the process of bleeding, we suggest the use of an exogenous blood clotting activator. This activator, alone or in combination with biomaterials, is capable of rapidly providing effective arrest of bleeding in surgery and in the field conditions.        

Video presentation of the project 

Project presentation in PDF format >>>

Additional materials:

Additional video on obtaining fibrin gel

FOR THE JURY >>>                                                                      FOR INVESTORS >>>

You can ask your questions about the project through the comments form


  1. What is the clotting activator? Is it a normal clotting factor? If so, which one? Is Carbohemostate a wound gauze containing the activator? Will the products need regulatory approval to enter the market?

  2. Nataliia LuhovskaAugust 6, 2021 at 4:26 AM

    Thank you for the question.
    Activator is not a compound of blood plasma and can be obtained using techniques developed in Palladin Institute of Biochemistry of NAS of Ukraine. Also we are developing the method of the obtaining of recombinant analogue of activator in the frame of State program for priority researches by Ministry of Sciences of Ukraine that will allow making the technology even cheaper.
    Blood clotting activator is a crucial compound of Carbohemostate. Carbohemostate is passing through clinical trials. Same activator is used for the preparation of fibrin glue and it is on the preclinical phase of trials.

    1. Thank you for the additional information.


Post a Comment

Contestants! Do not answer questions from an anonymous profile! (Учасники конкурсу! Не відповідайге на запитання з анонімного профілю!)